60 Degrees Pharmaceuticals (NASDAQ:SXTP) Receives Sell (E+) Rating from Weiss Ratings

Weiss Ratings reissued their sell (e+) rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research report sent to investors on Saturday morning,Weiss Ratings reports.

Separately, HC Wainwright reissued a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research note on Friday, January 10th.

60 Degrees Pharmaceuticals Stock Performance

Shares of SXTP stock traded up $0.00 on Friday, reaching $0.83. 322,501 shares of the company’s stock traded hands, compared to its average volume of 926,419. The business’s 50 day moving average price is $1.19 and its two-hundred day moving average price is $1.02. The company has a market capitalization of $1.90 million, a P/E ratio of -0.08 and a beta of 4.40. 60 Degrees Pharmaceuticals has a 12-month low of $0.70 and a 12-month high of $11.01.

Insider Transactions at 60 Degrees Pharmaceuticals

In other 60 Degrees Pharmaceuticals news, CEO Geoffrey S. Dow purchased 35,823 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were bought at an average price of $1.27 per share, for a total transaction of $45,495.21. Following the purchase, the chief executive officer now directly owns 94,580 shares in the company, valued at $120,116.60. This trade represents a 60.97 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders bought 66,372 shares of company stock valued at $82,410 in the last three months. Corporate insiders own 10.27% of the company’s stock.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.